analysis

Twitter: expediting critical research analysis 1:08
Twitter: expediting critical research analysis
Klaus Metzeler
Midostaurin: the first drug to receive approval for AML since 2000 2:28
Midostaurin: the first drug to receive approval for AML since 2000
Arnold Ganser • 4 May 2018
Current understandings of ALL approaches 2:24
Current understandings of ALL approaches
Charles Mullighan • 4 May 2018
Challenges with the identification of ALL subtypes 1:38
Challenges with the identification of ALL subtypes
Charles Mullighan • 4 May 2018
Myeloma XI trial: impact of MRD on treatment response in MM 1:19
Myeloma XI trial: impact of MRD on treatment response in MM
Graham Jackson • 9 Dec 2017
Multiple myeloma highlights at ASH 2017 1:34
Multiple myeloma highlights at ASH 2017
Graham Jackson • 9 Dec 2017
Results of the MURANO study for CLL 3:12
Results of the MURANO study for CLL
Arnon Kater • 9 Dec 2017
ASH 2017: CLL combination therapy highlights 2:19
ASH 2017: CLL combination therapy highlights
Arnon Kater • 9 Dec 2017
“Sequential triple-T” therapy for CLL 2:38
“Sequential triple-T” therapy for CLL
Barbara Eichhorst • 9 Dec 2017
Impacts of the MURANO study for future CLL treatment 1:10
Impacts of the MURANO study for future CLL treatment
Barbara Eichhorst • 9 Dec 2017
ASH 2017: combination therapy for CLL highlights 1:18
ASH 2017: combination therapy for CLL highlights
Barbara Eichhorst • 9 Dec 2017
Bendamustine plus rituximab vs. standard therapy for advanced CLL 2:19
Bendamustine plus rituximab vs. standard therapy for advanced CLL
Barbara Eichhorst • 9 Dec 2017
Front-line use of ibrutinib for CLL in a real-world setting 1:38
Front-line use of ibrutinib for CLL in a real-world setting
Anthony Mato • 9 Dec 2017
Retrospective multicenter analysis of venetoclax-treated CLL patients 3:36
Retrospective multicenter analysis of venetoclax-treated CLL patients
Anthony Mato • 9 Dec 2017
Triple therapy for CLL: pembrolizumab, ublituximab and umbralisib 3:21
Triple therapy for CLL: pembrolizumab, ublituximab and umbralisib
Anthony Mato • 9 Dec 2017
Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies 1:13
Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies
Anthony Mato • 9 Dec 2017
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals